Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location

Mantle Cell Lymphoma Clinical Trials

A listing of Mantle Cell Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (56) clinical trials

Pilot Study for Patients With Chemotherapy Resistant or Refractory CD19 Leukemia and Lymphoma

This is an open label, single center, pilot study to evaluate the safety and tolerability, and differential persistence and engraftment of autologous T cells engineered to express a chimeric antigen receptor targeting CD19 which is linked either to the CD3 or CD3:4-1BB signaling chains in a competitive repopulation setting in ...

Phase

Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

This study will evaluate the efficacy, safety, tolerability, and pharmacodynamics of entospletinib. Participants with the following relapsed or refractory hematologic malignancies will be enrolled into the study: relapsed or refractory chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or non-FL indolent non-Hodgkin ...

Phase

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

PRIMARY OBJECTIVES: I. To evaluate the safety of brentuximab vedotin and rituximab in patients with lymphoid malignancies that are cluster of differentiation (CD) 30 positive (+) and/or Epstein-Barr virus (EBV)+, and to determine the recommended phase 2 dose (RP2D) of the combination. (Phase I) II. To evaluate the efficacy, as ...

Phase

Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)

Relapsed and/or Refractory Mantle Cell Lymphoma (MCL): Study Drug Administration: If participant is found to be eligible for this study, participant will begin the first cycle of treatment with ibrutinib and rituximab. Each cycle is 28 days. Ibrutinib Administration: Every day participant will take 4 ibrutinib capsules with 1 cup ...

Phase

Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas

PRIMARY OBJECTIVES: I. Compare anti mullerian hormone (AMH), follicle stimulating hormone (FSH), and estradiol (E2) between patients at baseline and cross section of controls and again between patients at 12 months off therapy and cross section of controls. II. Describe the trajectory of AMH, FSH, and E2 from baseline to ...

Phase N/A

A Trial of Ibrutinib Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma

In this trial, patients with mantle cell lymphoma will be included, treatment with lenalidomide, rituximab and ibrutinib will be administered in an induction phase for up to 12 cycles, cycle length 28 days. Patients with complete remission, partial response or stable disease will enter a maintenance phase with treatment with ...

Phase

A Trial of Obinutuzumab GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients

The study will be conducted into 2 steps for respecting the optimal safety of the OASIS trial: Step A : The primary objective of step A is to evaluate the safety of the combination of GA101 + Ibrutinib at fixed doses (560 mg per day of Ibrutinib + 1000 mg ...

Phase

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.

Phase

BTK Inhibitor in B Cell Malignancies

M7583 is an investigational drug that is being evaluated for the treatment of patients with B-cell malignancies, which are cancers that form in B cells (cells that are part of the immune system). This study has been designed to assess the use of the study drug in patients with B-cell ...

Phase

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.

Phase